Yüklüyor......
Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case...
Kaydedildi:
| Yayımlandı: | Oxf Med Case Reports |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6440267/ https://ncbi.nlm.nih.gov/pubmed/30949354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/omcr/omz016 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|